Physician profile

Tabitha G Moe

Cardiovascular Disease · Phoenix, AZ

NPI 1508067588

$181,614.53

in general payments reported to CMS, 2019-2025

15 companies · $52K in 2025

The $52K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$146,105.31
Travel and Lodging$9,184.50
Food and Beverage$4,100.71
Education$98.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $88,707.74 2024-2025 Ozempic, Wegovy, Rybelsus
Boehringer Ingelheim Pharmaceuticals, INC. $74,886.60 2022-2025 Jardiance
Lilly USA, LLC $14,715.34 2022-2025 Jardiance
Medtronic, INC. $1,966.53 2023-2025 Harmony, Micra
Actelion Pharmaceuticals US, INC. $508.84 2022-2025 Uptravi, Opsumit, Opsynvi
Abbott Laboratories $245.79 2023-2024 Cardiomems
Boston Scientific Corporation $169.78 2021-2024 Watchman Flx
Atricure, INC. $114.36 2019
Edwards Lifesciences Corporation $105.44 2025 The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System
Janssen Pharmaceuticals, INC $103.49 2019
Cardiva Medical, INC. $73.12 2023 Cardiva Vascade 5f Vcs
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $17.50 2023 Lifevest

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tabitha G Moe

$181,614.53

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $52K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/68187/tabitha-g-moe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.